US 9,061,029 B2
METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITYGeneral
US 9,061,029 B2
METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Raymond Henley, III
Art Unit:
1629 Organic Chemistry
Agent:
Gregory Houghton
Inventors:
Neil Gallagher; Ophelia Yin
Assignee:
Priority:
11/17/10
Filed:
05/14/12
Granted:
06/23/15
Expiration:
04/08/31
Abstract
The present invention relates to a regimen for the administration of a pyrimidylaminobenzamide of formula Iwherein the radicals as defined herein, or of a pharmaceutically acceptable salt thereof, for the treatment of proliferative disorders, particularly solid and liquid tumors, and other pathological conditions mediated by the Bcr-Abl oncoprotein, the cell transmembrane tyrosine kinase receptor c-Kit, DDR1 (discoidin domain receptor 1), DDR2 (discoidin domain receptor 2) or PDGF-R (platelet derived growth factor receptor) kinase activity, wherein the pyrimidylaminobenzamide of formula I and, optionally, pharmaceutically acceptable carriers, are dispersed in a fruit preparation.
Cooperative Patent Classification (CPC)
A61A61P37/06A61K9/0095A61PC07D239/69C07D